This is a working overview of PPARδ, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
===== Transcription ===== Once a virus genome becomes operational in a host cell, it then generates messenger RNA (mRNA) molecules that direct the synthesis of viral proteins. Production of mRNA is initiated by proteins known as transcription factors. Several antivirals are now being designed to block attachment of transcription factors to viral DNA.
=== General references === Ambrose, W.; Novak, S.W.; Abdelrehim, I. (2004). "Powdered obsidian for determining hydration rates and site thermometry". Mediterranean Archaeology and Archaeometry. 4 (2): 17–31. Liritzis (2006). "SIMS-SS A new obsidian hydration dating method: analysis and theoretical principles". Archaeometry. 48 (3): 533–547. Bibcode:2006Archa..48..533L. doi:10.1111/j.1475-4754.2006.00271.x. Rogers, A. K. (2008). "Field data validation of an algorithm for computing obsidian effective hydration temperature". Journal of Archaeological Science. 35 (2): 441–447. Bibcode:2008JArSc..35..441R. doi:10.1016/j.jas.2007.04.009. Eerkens, J.W; Vaughn, K.J; Carpenter, T.R; Conlee, C.A; Linares Grados, Moises; Schreiber, K (2008). "Obsidian hydration dating on the South Coast of Peru". Journal of Archaeological Science. 35 (8): 2231–2239. Bibcode:2008JArSc..35.2231E. doi:10.1016/j.jas.2008.02.009. Liritzis, I; Laskaris, N (2009). "Advances in obsidian hydration dating by secondary ion mass spectrometry: World examples". Nuclear Instruments and Methods in Physics Research Section B. 267 (1): 144–150. Bibcode:2009NIMPB.267..144L. doi:10.1016/j.nimb.2008.10.092.
The TAAR1 full agonist RO5166017 and the high-efficacy TAAR1 partial agonist RO5256390, as well as the antipsychotic olanzapine, produced similar effects in these paradigms. Relatedly, RO5263397 produced a pattern of brain activity in rodents similar to that of antipsychotics. In addition, RO5263397 potently suppresses hyperlocomotion in dopamine transporter (DAT) knockout mice. The preceding findings suggest that TAAR1 agonists like RO5263397 have antipsychotic-like properties. In contrast to classical antipsychotics however, RO5263397 did not show extrapyramidal-like symptoms like catalepsy in mice, and instead partially prevented haloperidol-induced catalepsy, suggesting the potential for an improved tolerability profile. RO5263397 has been shown to reduce behavioral sensitization induced by cocaine in mice. Similarly, it reduces the expression but not development of conditioned place preference (CPP) by cocaine in mice. Analogously to cocaine, RO5263397 dose-dependently attenuates behavioral sensitization to methamphetamine, reduces self-administration of methamphetamine, and blocks reinstatement of methamphetamine-seeking behaviors in rodents. It also attenuates methamphetamine-induced impulsivity in rodents. In general, the drug has been found to suppress methamphetamine-, cocaine, and nicotine-induced stimulant-like and reinforcing effects in animals in vivo. Analogous findings have been made for morphine and ethanol. RO5263397 has similar effects compared to TAAR1 full agonists like RO5256390 in vivo in terms of psychostimulant modulation.
=== seg-seo === seganserin (INN) seglitide (INN) Sehippy seladelpar (INN) selamectin Selarsdi Selax Seldane Selecor Select 1/35 Selectol selegiline (INN) selenomethionine (75 Se) (INN) Selepen selepressin (INN) Selestoject seletracetam (USAN, (INN)) selexipag (INN) selfotel (INN) seliciclib (INN) selodenoson (USAN) Selpak selprazine (INN) Selsun Selsun Blue seltraposin (INN) selumetinib (USAN) selurampanel (INN) selvacovatein (INN) semagacestat (USAN, INN) semaglutide (INN) sematilide (INN) semduramicin (INN) Semicid Semilente semorphone (INN) semotiadil (INN) semparatide (INN) Semprex-D semuloparin (USAN, INN) semustine (INN) Senexon senicapoc (USAN) Sennatural senofilcon A (USAN) Senokot Senolax Sensipar Sensorcaine Senvelgo seocalcitol (INN)
Sources: en.wikipedia.org
== Structure == Lysine carboxypeptidase has a molecular weight of between 270 and 330 kDa (kilodaltons). It is a tetrameric glycoprotein. It is composed of two 83 kDa subunits and two active subunits between 55 kDa and 48 kDa and these are held together by non-covalent interactions. The 83 kDa subunits are regulatory and do not directly contribute to catalytic activity; they are also heavily glycosylated. These function to stabilize the active subunits and keep them in circulation. Catalytic functioning is retained when the 83 kDa subunits are eliminated from the active subunits, but they are still necessary for their support roles. The active subunits are small and relatively unstable at body temperature and blood pH, so they would not last long in the plasma without the regulatory subunits attached. The 55 kDa-48 kDa portions are both catalytically active. The primary structure of the 83 kDa subunit can be split into three main domains. The first domain is located at the N-terminus and consists of 52 amino acids with the first 27 being cysteine-rich. The second domain refers to the next 312 amino acids and it consists of 13 leucine-rich repeat (LRR) sections, each made up of 24 residues. The final C-terminal domain refers to the last 145 residues where amino acids 400-425 hold a cysteine-rich section. The secondary/tertiary structure of the subunit has not yet been experimentally determined, but it has been hypothesized based upon how other LRR proteins fold.
Ion-exchange chromatography separates molecules based on their respective charged groups. Ion-exchange chromatography retains analyte molecules on the column based on coulombic (ionic) interactions. The ion exchange chromatography matrix consists of positively and negatively charged ions. Essentially, molecules undergo electrostatic interactions with opposite charges on the stationary phase matrix. The stationary phase consists of an immobile matrix that contains charged ionizable functional groups or ligands. The stationary phase surface displays ionic functional groups (R-X) that interact with analyte ions of opposite charge. To achieve electroneutrality, these immobilized charges couple with exchangeable counterions in the solution. Ionizable molecules that are to be purified, compete with these exchangeable counterions, for binding to the immobilized charges on the stationary phase. These ionizable molecules are retained or eluted based on their charge. Initially, molecules that do not bind or bind weakly to the stationary phase are first to be washed away. Altered conditions are needed for the elution of the molecules that bind to the stationary phase. The concentration of the exchangeable counterions, which competes with the molecules for binding, can be increased, or the pH can be changed to affect the ionic charge of the eluent or the solute. A change in pH affects the charge on the particular molecules and, therefore, alter their binding. When reducing the net charge of the solute's molecules, they start eluting out.
Migraine was first comprehensively classified in 1988, when the International Headache Society (IHS) began its classification of headache disorders. The IHS updated its classification of headaches in 2004, and a third version was published in 2018. According to this classification, migraine is a primary headache disorder along with tension headaches and cluster headaches. The classification of migraine includes six broad categories:
Sources: en.wikipedia.org
== Structure == SUMO proteins are small; most are around 100 amino acids in length and 12 kDa in mass. The exact length and mass varies between SUMO family members and depends on which organism the protein comes from. Although SUMO has very little sequence identity with ubiquitin (less than 20%) at the amino acid level, it has a nearly identical structural fold. SUMO protein has a unique N-terminal extension of 10-25 amino acids which other ubiquitin-like proteins do not have. This N-terminal is found related to the formation of SUMO chains. The structure of human SUMO1 is depicted on the right. It shows SUMO1 as a globular protein with both ends of the amino acid chain (shown in red and blue) sticking out of the protein's centre. The spherical core consists of an alpha helix and a beta sheet. The diagrams shown are based on an NMR analysis of the protein in solution.
On the other hand, many of the potentials used in physics, such as those based on the bond order formalism can describe several different coordinations of a system and bond breaking. Examples of such potentials include the Brenner potential for hydrocarbons and its further developments for the C-Si-H and C-O-H systems. The ReaxFF potential can be considered a fully reactive hybrid between bond order potentials and chemistry force fields.
Wastewater treatment plants (WWTPs) are designed to remove contaminants from domestic and industrial wastewater before it is released into the environment. However, some WWTPs, particularly older or under-resourced ones are not equipped to effectively remove all CEC, such as advanced pharmaceuticals, personal care product ingredients, and certain types of industrial chemicals. These substances can pass through the treatment process and enter aquatic ecosystems, which creates a challenge for water treatment technology and emphasizes the need for ongoing research and infrastructure improvement to address the removal of CEC from wastewater. Advances like tertiary treatment stages, which incorporate advanced filtration and chemical removal techniques, are being tested to address the presence of CEC in waste, though widespread implementation is yet to be seen due to novelty, cost, and logistical challenges.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.